Position statement of the SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC

Huelgas, Ricardo Gómez; Peralta, Fernando Gómez; Fernández, Lourdes Carrillo; Galve, Enrique; Casanueva, Felipe F.; Domingo, Manuel Puig; Bravo, José Javier Mediavilla; Orozco-Beltrán, Domingo; Muñoz, Javier Ena; Torre, Edelmiro Menéndez; Menéndez, Sara Artola; Ramos, Pilar Mazón; Megías, Susana Monereo; Pedragós, Assumpta Caixàs; Simarro, Flora López; Guisasola, Fernando Álvarez

doi:10.1016/j.rceng.2015.09.004

Cited by 3 publications

(5 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association between obesity and less PA among people with diabetes is especially relevant due to the benefit in glycemic control and the cardiovascular risk profile of weight loss that can be achieved with PA [ 2 , 9 , 29 ]. Intervention approaches in this subgroup of patients should be individualized, multidisciplinary, and always considering their specific barriers to PA [ 2 , 9 , 29 , 43 ].…”

Section: Discussionmentioning

confidence: 99%

“…Efforts directed at the general population will result in an improvement in the population with diabetes, but it is important to implement lifestyle improvement programs specifically aimed at the most vulnerable groups of people with diabetes, such as females, the elderly, and obese individuals, to help them to initiate and maintain the benefits of an active lifestyle. Linking exercise to leisure and socialization can be a particularly positive strategy in these patients [ 2 , 42 , 43 , 44 , 45 ].…”

Section: Discussionmentioning

confidence: 99%

“…The recommendation of exercise must be individualized and centered on the patient with diabetes, and a comprehensive and multidisciplinary approach, which can be optimized by including graduates in physical activity and sports sciences in therapeutic teams. Mobile health interventions (mHealth) can represent an alternative or complement to face-to-face programs, although their results still require further effectiveness studies [ 42 , 43 , 44 , 45 , 46 ].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Cross Sectional and Case-Control Study to Assess Time Trend, Gender Differences and Factors Associated with Physical Activity among Adults with Diabetes: Analysis of the European Health Interview Surveys for Spain (2014 & 2020)

Llamas-Saez

Sáez-Vaquero

Jiménez‐García

et al. 2023

JCM

View full text Add to dashboard Cite

(1) Background: We aim to assess the time trend from 2014 to 2020 in the prevalence of physical activity (PA), identify gender differences and sociodemographic and health-related factors associated with PA among people with diabetes, and compare PA between people with and without diabetes. (2) Methods: We conducted a cross-sectional and a case–control study using as data source the European Health Interview Surveys for Spain (EHISS) conducted in years 2014 and 2020. The presence of diabetes and PA were self-reported. Covariates included socio-demographic characteristics, health-related variables, and lifestyles. To compare people with and without diabetes, we matched individuals by age and sex. (3) Results: The number of participants aged ≥18 years with self-reported diabetes were 1852 and 1889 in the EHISS2014 and EHISS2020, respectively. The proportion of people with diabetes that had a medium or high frequency of PA improved from 48.3% in 2014 to 52.6% in 2020 (p = 0.009), with 68.5% in 2014 and 77.7% in 2020 being engaged in two or more days of PA (p < 0.001). Males with diabetes reported more PA than females with diabetes in both surveys. After matching by age and gender, participants with diabetes showed significantly lower engagement in PA than those without diabetes. Among adults with diabetes, multivariable logistic regression showed confirmation that PA improved significantly from 2014 to 2020 and that male sex, higher educational level, and better self-rated health were variables associated to more PA. However, self-reported comorbidities, smoking, or BMI > 30 were associated to less PA. (4) Conclusions: The time trend of PA among Spanish adults with diabetes is favorable but insufficient. The prevalence of PA in this diabetes population is low and does not reach the levels of the general population. Gender differences were found with significantly more PA among males with diabetes. Our result could help to improve the design and implementation of public health strategies to improve PA among people with diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cross Sectional and Case-Control Study to Assess Time Trend, Gender Differences and Factors Associated with Physical Activity among Adults with Diabetes: Analysis of the European Health Interview Surveys for Spain (2014 & 2020)

Llamas-Saez

Sáez-Vaquero

Jiménez‐García

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…Although weight loss should be an objective in patients with obesity and diabetes, it should not be a determinant for the prescription of GLP-1 RAs. The benefits of glucose control and reduction of CV risk with GLP-1 RAs have also been proven in non-obese patients with T2D [ 16 , 21 , 37 ]. However, although the limitation by the Spanish National Health Service could affect the use of GLP-1 RAs, it may not be the major reason for the majority of patients, as other countries without the BMI limitation have similar prescription rates as Spain [ 26 , 38 , 39 ].…”

Section: Potential Reasons That Limit the Use Of Glp-1 Ras Based On T...mentioning

confidence: 99%

“…Yet other guidelines offer a combined approach and advise use of GLP-1 RAs in patients with CVD and/or high BMI [ 2 , 18 – 20 ]. Guidelines in Spain underscore that the adequate treatment of T2D requires a simultaneous approach to HbA1c, overweight/obesity, and other CV risk factors such as hypertension, dyslipidaemia or smoking, and highlight that the presence of CVD is a determinant factor for treatment selection [ 2 , 21 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice

et al. 2023

View full text Add to dashboard Cite

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a class of drugs with potent glucoselowering activity. Additionally, some GLP-1 RAs have demonstrated cardiovascular and renal benefits. Current guidelines recommend their use in patients with type 2 diabetes (T2D) at high risk of or with established cardiovascular disease (CVD), regardless of glycaemic control, with lifestyle modification and metformin. However, several studies have recently highlighted the limited number of patients with T2D benefiting from these medications worldwide. Given the huge burden of CVD among patients with T2D, efforts should be made to bring clinical practice closer to expert guidelines. This review describes the current situation of GLP-1 RA use in Spain and the reasons behind the gap between guidelines and realworld practice and suggests possible solutions.

show abstract

<p>Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy</p>

Gómez-Peralta¹,

Abreu²

2019

DDDT

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) has become one of the leading causes of morbidity and mortality in developed countries. Low efficacy, weight gain, and hypoglycemia are the main pitfalls of previous treatments for T2DM. New therapies have been designed with the aim of improving the results in efficacy and quality of life. Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RA) increase glucose-dependent insulin secretion, decrease gastric emptying, and reduce postprandial glucagon secretion. The last GLP-1 RA approved by the US Food and Drug Administration and European Medicines Agency was semaglutide. This review describes its pharmacology, core clinical data coming from the randomized controlled trials included in the development program, proven cardiovascular benefits, safety issues, and precautions for the use of semaglutide in special populations. Additionally, an overview of the positioning of semaglutide in T2DM therapy and practical issues regarding semaglutide initiation are offered.

show abstract

Position statement of the SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC

Cited by 3 publications

References 91 publications

Cross Sectional and Case-Control Study to Assess Time Trend, Gender Differences and Factors Associated with Physical Activity among Adults with Diabetes: Analysis of the European Health Interview Surveys for Spain (2014 & 2020)

Cross Sectional and Case-Control Study to Assess Time Trend, Gender Differences and Factors Associated with Physical Activity among Adults with Diabetes: Analysis of the European Health Interview Surveys for Spain (2014 & 2020)

GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice

<p>Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy</p>

Contact Info

Product

Resources

About